Last month, we announced a strategic shift in our US weight loss business that reflects the market transformation in FDA-approved GLP-1 treatments. More affordable prices, with more flexible dosing options and greater diversity of form factors, means more people can find an FDA-approved treatment that best fits their budget, goals, and daily life.
As part of this shift, we formed a collaboration with Novo Nordisk to help customers access Wegovy® injections and pills.
Today we’re taking another step: we’ve expanded our platform’s functionality so that providers delivering ongoing care to Hims & Hers customers can prescribe medications that are fulfilled by independent pharmacies.
Now, providers on our platform can send prescriptions for Zepbound® vials and KwikPen®, as well as Foundayo™, to the LillyDirect® pharmacy and access self-pay pricing for Hims & Hers customers1. This functionality, supported by our weight loss membership, is how licensed providers on Hims & Hers can now help their patients access the full range of FDA-approved GLP-1 medication at the lowest prices available.
Every weight loss journey on Hims & Hers is supported by our membership experience, which includes comprehensive support services, 24/7 direct access to a care team, personalized nutrition guidance, ongoing clinical check-ins, and peer support in the Hims & Hers Weight Loss community.
Our goal is to ensure that when Hims & Hers customers trust us with their health journey, they have access to a diverse range of treatment options alongside a comprehensive care experience. This is all part of giving customers more ways to start and help sustain their health journey based on their unique history, preferences, needs, and goals.
For more information, visit www.hims.com/weight-loss or www.forhers.com/weight-loss
1Access to Zepbound and Foundayo does not imply a partnership or affiliation with Eli Lilly and Company. Any licensed healthcare provider can prescribe to a LillyDirect® pharmacy. More information at: https://www.lilly.com/lillydirect/hcp
Wegovy® is a registered trademark of Novo Nordisk A/S. Zepbound®, KwikPen®, and LillyDirect® are registered trademarks, and Foundayo™ is a trademark of Eli Lilly and Company. Hims, Inc. is not affiliated with or endorsed by Eli Lilly and Company.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “coming,” “starting,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the offerings and services accessible on our platform, statements regarding future collaborations, functionality or expanded access to treatment options; and statements regarding the membership model. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to updating access to the offerings available on our platform, and the related customer response; the timing or feasibility of potential future partnerships or collaborations or expanded access to treatment options available on our platform; changes in the application, interpretation, and enforcement of healthcare, consumer protection or privacy laws or regulations applicable to our business; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of April 23, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
